Tenet Healthcare (THC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
Annual meeting scheduled for May 27, 2026, to be held virtually for shareholders of record as of April 2, 2026.
Proxy materials, including the Notice of Annual Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Shareholders will vote on the election of 12 director nominees.
Advisory vote on executive compensation is included as Proposal 2.
Ratification of Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026, is Proposal 3.
Board recommends voting FOR all director nominees and FOR Proposals 2 and 3.
Board of directors and corporate governance
Twelve director nominees are listed for election, including Saumya Sutaria, J. Robert Kerrey, Vineeta Agarwala, and others.
Latest events from Tenet Healthcare
- Q2 2026 delivered strong profit growth, higher guidance, and major capital deployment.THC
Q2 2026 - High-acuity focus and disciplined capital deployment drive growth amid policy uncertainty.THC
Barclays 27th Annual Global Healthcare Conference - Sequential volume recovery and high acuity focus drive confidence in annual growth targets.THC
Bank of America Global Healthcare Conference 2026 - Q1 2026 net income jumped 73% to $702M, with strong EBITDA and robust cash flow.THC
Q1 2026 - 2025 performance exceeded targets, supporting high executive pay and strong shareholder returns.THC
Proxy filing - Q3 net income soared to $472M on asset sales, with EBITDA up 15% and FY guidance raised.THC
Q3 2024 - Q2 2024 Adjusted EBITDA up 12% to $945M; FY 2024 guidance and buybacks increased.THC
Q2 2024 - Q1 2025 Adjusted EBITDA up 14%, margin gains, strong cash flow, and $348M in buybacks.THC
Q1 2025 - Q4 and FY 2024 results show margin expansion, deleveraging, and robust ambulatory growth.THC
Q4 2024